"JAD and IOS Press are honored to be working with ISOA, one of the preeminent private foundations in Alzheimer's disease research, on this timely issue," says George Perry, PhD, Editor-in-Chief of JAD.
Designed to help further the advancement of drug discovery for neurodegenerative diseases, the conference – New Directions in Neuroprotection: Basic Mechanisms, Molecular Targets and Treatment Strategies – was held 3-4 June 2004 in New York. This gathering of leading researchers in Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis and other neurodegenerative disorders was highlighted by 15 contributions addressing potential therapies and treatments for these devastating illnesses.
Writing in the lead article, Lorenzo M. Refolo, Ph.D., scientific director of ISOA, and Howard M. Fillit, M.D., executive director of ISOA, state, "The development of therapies for the neurodegenerative disease represents a major challenge to academic, biotechnology and pharmaceutical scientists. Current therapies for the neurodegenerative diseases provide effective symptomatic relief, particularly in early stages of disease. However, there are too few, if any therapies that affect the underlying disease processes. Therefore, disease-modifying therapies that halt, slow or reverse disease progression are sorely needed. It is expected that, next generation of neuroprotective therapies will stop and/or slow neuronal cell death and will therefore be disease modifying. This timely catalyst conference was sponsored by Forest Laboratories. We are pleased to be working with IOS Press in publishing this important work."
©2004 IOS Press. All rights reserved. Unauthorized use prohibited.
About the Journal of Alzheimer's Disease
The Journal of Alzheimer's Disease (www.j-alz.com) is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer's disease. The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. The journal is dedicated to providing an open forum for original research that will expedite our fundamental understanding of Alzheimer's disease.
About IOS Press
Commencing its publishing activities in 1987, IOS Press (www.iospress.com) is a rapidly expanding scientific, technical, medical and professional publishing house focusing on a broad range of subject areas. Headquartered in Amsterdam, IOS Press publishes approximately 100 new books per annum and 70 international journals, covering topics ranging from computer science and mathematics to medicine and the natural sciences. Electronic access to all journals is now available. IOS Press also maintains offices in the Washington, DC area and Berlin and a co-publishing relationship with Ohmsha, Ltd (Tokyo).
ISOA (www.aging-institute.org) is a biomedical venture philanthropy founded by the Estee Lauder family, whose mission is to catalyze and fund the discovery and development of new therapies to prevent and treat cognitive aging and Alzheimer's disease. Since 1998, ISOA has committed more than $22 million in support of 128 research projects and conferences at leading academic institutions and biotechnology companies worldwide.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.